Threats and Opportunities Associated with the Implementation of Performance based Managed Entry Agreements in Slovakia

Slovakia has adopted an amendment to the of Act No. 363/2011 regulating, among other things, drug reimbursement and is undergoing a significant change in the availability of innovative treatments for patients. The main objective of this qualitative research was to analyse the opinions, views and perceptions of Slovak stakeholders with regard to performance-based managed entry agreements (PB-MEA) as facilitated by the recent amendment. The survey was carried out on a sample of 12 stakeholders. The responses were analysed using MAXQDATA 2022 software. The results showed that there are some positive expectations towards the nation-wide implementation of the PBMEA such as better availability of medicines, emphasis on the patient. A significant number of threats were also identified such as procedural unpreparedness and problems with data availability.